The three largest pharmacy benefit managers are now divisions of the three largest managed care companies. This is not an organizational coincidence—it is a structural integration that has profound implications for how hospital pricing, pharmaceutical pricing, and insurance margins interact.
UnitedHealth Group owns OptumRx. CVS Health owns Caremark and also owns Aetna. Cigna owns Express Scripts. Together, these three entities manage the pharmacy benefits for a majority of commercially insured Americans—and their parent companies simultaneously negotiate hospital rates that, through platforms like MedPricer.org, are now partially visible. The integration creates leverage that runs through multiple dimensions: combined medical and pharmacy cost data gives these entities actuarial advantages in pricing, cross-referral relationships between medical and pharmacy networks, and administrative data integration that competitors without vertical integration cannot replicate.
For a fund running a position in a vertically integrated managed care company, MedPricer’s hospital rate data helps answer a specific question: is the integrated company using its combined leverage to negotiate hospital rates that are below market, or are its hospital rates tracking market averages despite the integration? If the former, the integration produces a tangible cost advantage that should be visible in MLR performance. If the latter, the integration benefits are primarily administrative or pharmaceutical rather than hospital contract-based.
The cross-sector signal framework works as follows. In markets where a vertically integrated MCO has both dominant MA enrollment and dominant PBM market share, its hospital negotiating leverage should be, theoretically, superior to that of a stand-alone insurer. A stand-alone insurer can only threaten exclusion from its medical network. An integrated MCO can also threaten to direct members to mail-order pharmacy for specialty drug dispensing—a substantial revenue stream for hospital-affiliated specialty pharmacies. This cross-leverage hypothesis is testable through MedPricer data: do integrated MCOs show lower hospital rates in markets where they also have dominant PBM share?
The data quality constraints are significant. PBM market share by geography is not directly disclosed; it must be estimated from employer benefit filings, state insurance reports, and industry surveys. Hospital rates in MedPricer are at the payer-procedure level, but identifying which payer entity corresponds to which parent MCO requires navigating the complex subsidiary structures of large integrated companies.
None of these challenges is insurmountable, but they require the kind of institutional knowledge about healthcare market structure that generalist analysts lack. Healthcare-specialist hedge funds that have invested in this domain expertise gain a material edge over generalists who model managed care companies from 10-K disclosures and sell-side summaries.
The regulatory risk is material and asymmetric. PBM practices are under intense scrutiny from the FTC, which released a critical report on PBM practices in 2024 documenting vertical integration concerns, formulary manipulation, and spread pricing. Legislative action restricting PBM practices—carve-out mandates, spread pricing prohibitions, rebate pass-through requirements—would differentially affect vertically integrated MCOs relative to independent PBMs. A fund with hospital rate data through MedPricer and PBM practice knowledge from FTC filings is better positioned to assess this regulatory risk.
The cross-sector framework ultimately reflects a structural reality about healthcare economics: the entities that negotiate hospital prices, manage pharmaceutical benefits, and underwrite insurance risk are increasingly the same entities. Analyzing them in isolation produces models that miss the interactions. MedPricer’s hospital rate data is one input into a more integrated analytical framework—valuable precisely because it reveals one side of a multi-sided strategic positioning.
